Paragon 28, Inc.

Paragon 28, Inc.

FNA

$13.09

Updated: 22/09/2026, 12:09:03

Market Cap
$1.10B
Sector
Healthcare
Industry
Medical - Devices
Country
US

No historical data available

Company Profile

Paragon 28, Inc. is a medical device company specializing in the development, manufacturing, and global distribution of advanced surgical systems tailored for foot and ankle procedures. Its comprehensive product portfolio encompasses a wide array of solutions: Plating Systems: This includes the Gorilla plating series, offering specific solutions for Lisfranc injuries, Lapidus procedures, lateral column corrections, calcaneus slides, and naviculocuneiform (NC) fusions. Complementary products like Baby Gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates, as well as Silverback plating systems, are also available. Precision Guidance Technology: The company provides sophisticated guidance systems to enhance accuracy in various operations, such as fusion procedures for bunion deformities, first tarsometatarsal arthrodesis, metatarsal osteotomy for bunion correction, medial column beaming for Charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. Screw Systems: Paragon 28 offers robust screw systems, including the Monster, Mini Monster, and Joust beaming lines, which are critical for applications like bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, and fracture repair. Joint Replacement Solutions: Their offerings extend to total ankle replacement with the APEX 3D systems, alongside total talus spacers designed to replace the talus bone that links the leg and foot. Bunion/Hallux Valgus Correction Systems: Specifically for bunion management, the company provides nail systems such as the Phantom intramedullary nail systems, targeting severe hallux valgus cases. Orthobiologics: A substantial part of their product line comprises various orthobiologics, including bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix. They also feature PRESERVE bone graft systems for homologous applications. Ancillary Products: The company further supplies soft tissue fixation systems, titanium sprayed polyetheretherketone (PEEK) implants, nitinol staple systems, stabilization solutions, and specialized curved instruments. Paragon 28 distributes its products to hospitals and ambulatory surgery centers through an established network of both direct sales representatives and stocking distributors. Founded in 2010, the company maintains its corporate headquarters in Englewood, Colorado.

USD
NYSE
CEO: Albert DaCosta
Employees: 525
https://www.paragon28.com
Asset Summaries
Latest generated summaries for FNA

No summaries found.

Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for FNA.
Share price
$13.09
Market cap
$1.10B
Exchange
NYSE
Currency
USD
CEO
Albert DaCosta
Employees
525
IPO date
15/10/2021
Beta
1.473
Last dividend
$0.00
Day range
$13.07 – $13.11
52-week range
$4.65 – $13.13
1-day performance
0.00%
1-year performance
181.51%
Current drawdown (1Y)
-0.30%
CIK
0001531978
CUSIP
69913P105
ISIN
US69913P1057
Created
07/12/2025, 04:02:54
Last update
22/09/2026, 12:09:03

Track Paragon 28, Inc. with an AI analyst

See which prediction-market events move FNA, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to FNA from your Railway `news_articles` table.

No news found for this symbol.